QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 1.0E-6
-- x --
-- x --
-- - --
$ 0.00 - $ 0.02
1,700
na
na
$ 53.56
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pear-therapeutics-receives-fda-breakthrough-device-designation-for-prescription-digital-therapeutic-candidate-to-treat-alcohol-use-disorder

Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital ther...

 november-spac-merger-calendar-upcoming-votes-earnings-stocks-to-watch

The month of November shows a continued slowdown in SPAC merger deal votes, but the calendar includes several multibillion-doll...

 thimble-point-acquisition-pear-therapeutics-announce-effectiveness-of-s-4-registration-statement-set-nov-23-2021-for-vote-on-proposed-business-combination

Pear Therapeutics, Inc. ("Pear"), the leader in developing and commercializing prescription digital therapeutics ("...

 14-spacs-that-palantir-technologies-has-invested-in-or-partnered

Palantir Technologies Inc (NYSE: PLTR) is one of the most well-known publicly traded companies. The data analytics company is i...

 pear-therapeutics-to-go-public-through-merger-with-thimble-point-acquisition-corp-acquisition-represents-equity-value-of-16b

Pear Therapeutics, Inc. ("Pear") has built the first end-to-end platform for prescription digital therapeutics (PDTs)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION